Table 4.
Risk of developing respiratory failure and nonrelapse related mortality according to pretransplant DLCO categories and PAM score
| Number of cases (%) | Hazard ratio (95% Confidence interval) | P-value | |
|---|---|---|---|
| Respiratory failure* | 66 | ||
| Percent of predicted DLCO | |||
| 50%–60% | 47/167 (28) | Referent | - |
| 40%–49% | 14/40 (35) | 1.37 (0.76–2.49) | 0.298 |
| <40% | 5/14 (36) | 1.50 (0.60–3.78) | 0.388 |
| Nonrelapse mortality* | 131 | ||
| Percent of predicted DLCO | |||
| 50%–60% | 92/167 (55) | Referent | - |
| 40%–49% | 29/40 (73) | 1.28 (0.88–1.87) | 0.198 |
| <40% | 10/14 (71) | 1.37 (0.77–2.42) | 0.282 |
| PAM score categories† | |||
| Quartile 1 (17–27) | 28/37 (76) | Referent | - |
| Quartile 2 (28–31) | 18/34 (53) | 1.78 (1.08–2.95) | 0.025 |
| Quartile 3 (32–33) | 28/55 (51) | 2.27 (1.42–3.65) | 0.001 |
| Quartile 4 (35–42) | 30/39 (77) | 4.38 (2.69–7.14) | <0.001 |
*
Analysis includes autologous and allogeneic transplant patients (Total N=221)
†
Analysis restricted to nonrelapse mortality among allogeneic transplant patients (Total N=165)